Cargando…
Post-marketing Surveillance of a Quadrivalent Influenza Vaccine (Vaxigrip Tetra) in South Korea
INTRODUCTION: In 2017, a quadrivalent inactivated split-virion influenza vaccine (QIV; Vaxigrip Tetra(®), Sanofi) was licensed in South Korea for active immunization against influenza A and influenza B viruses in individuals aged 3 years or older, which was subsequently extended to individuals aged...
Autores principales: | Lim, Sookyung, Li, Xiaoling, Syrkina, Olga, Fournier, Marion |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9450834/ https://www.ncbi.nlm.nih.gov/pubmed/36070176 http://dx.doi.org/10.1007/s40121-022-00685-x |
Ejemplares similares
-
Post-Marketing Safety Surveillance of Quadrivalent Influenza Vaccine (VaxigripTetra) in Children Aged 6 to 35 Months in South Korea
por: Choe, Sunho, et al.
Publicado: (2023) -
Immunogenicity and Safety of the New Inactivated Quadrivalent Influenza Vaccine Vaxigrip Tetra: Preliminary Results in Children ≥6 Months and Older Adults
por: Montomoli, Emanuele, et al.
Publicado: (2018) -
Enhanced passive safety surveillance of a quadrivalent inactivated split virion influenza vaccine in Finland during the influenza season 2020/21
por: Syrkina, Olga, et al.
Publicado: (2022) -
Assessment of the influenza vaccine (VAXIGRIP) in triggering a humoural immune response
por: Mahallawi, Waleed H.
Publicado: (2017) -
Enhanced passive safety surveillance of high‐dose and standard‐dose quadrivalent inactivated split‐virion influenza vaccines in Germany and Finland during the influenza season 2021/22
por: Gandhi‐Banga, Sonja, et al.
Publicado: (2022)